Sugi Predict

Sugi Predict / Compounds / SCHEMBL6714743

SCHEMBL6714743

SCHEMBL6714743

CNC(C(=O)O)c1ccc(O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 3/20 0.55
▸ NAALAD2 Q9Y3Q0 1/20 0.47
▸ SRC P12931 1/20 0.46
▸ ESR1 P03372 4/20 0.43
▸ ESR2 Q92731 3/20 0.43
▸ PDCD1 Q15116 1/20 0.43
▸ CD274 Q9NZQ7 1/20 0.43
▸ CYP2C9 P11712 3/20 0.42
▸ TDP1 Q9NUW8 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ HTR1A P08908 1/20 0.42
▸ THPO P40225 1/20 0.42
▸ BLM P54132 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ NMUR2 Q9GZQ4 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ TAAR1 Q96RJ0 1/20 0.42
▸ KMT2A Q03164 3/20 0.41
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5427932 1.00 FOLH1 (0.55) FOLH1NAALAD2SRCESR1ESR2
SCHEMBL31173416 1.00 FOLH1 (0.55) FOLH1NAALAD2SRCESR1ESR2
Hydrochloric Acid SCHEMBL1971853 0.98 FOLH1 (0.54) FOLH1NAALAD2SRCESR1ESR2
Hydrochloric Acid SCHEMBL5376242 0.98 FOLH1 (0.54) FOLH1NAALAD2SRCESR1ESR2
Hydrochloric Acid SCHEMBL1971852 0.98 FOLH1 (0.54) FOLH1NAALAD2SRCESR1ESR2
SCHEMBL23314786 0.83 ESR1 (0.47) FOLH1NAALAD2SRCESR1ESR2
SCHEMBL15787299 0.83 LMNA (0.44) FOLH1TDP1ALDH1A1SMN1; SMN2LMNA
SCHEMBL15787345 0.83 LMNA (0.44) FOLH1TDP1ALDH1A1SMN1; SMN2LMNA
SCHEMBL19546313 0.83 ESR1 (0.47) FOLH1NAALAD2SRCESR1ESR2
SCHEMBL1964866 0.83 CYP2D6 (0.50) NAALAD2SRCCYP2C9TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040101523-A1 Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension G.D. SEARLE & CO. 2004-05-27 — — US claimed
US-20030220521-A1 Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension G.D. SEARLE & CO. 2003-11-27 — — US claimed
WO-1991001724-A1 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION G.D. SEARLE & CO. (US) 1991-02-21 — — WO claimed
EP-3377473-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2024-06-19 — — EP disclosed
EP-4371982-A2 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX Pharmaceuticals, Inc. (US) 2024-05-22 — — EP disclosed
EP-3583096-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2024-03-27 — — EP disclosed
EP-3377474-B1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-08-16 — — EP disclosed
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 — — US disclosed
CN-110520413-B Macrocyclic broad spectrum antibiotics 阿奇克斯制药公司 2023-02-17 — — CN disclosed
CN-108884058-B Macrocyclic broad spectrum antibiotics 阿奇克斯制药公司 2022-04-29 — — CN disclosed
CN-109219596-A MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS 阿奇克斯制药公司 2019-01-15 — — CN disclosed
CN-108884058-A MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS 阿奇克斯制药公司 2018-11-23 — — CN disclosed
US-20180327367-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS WUXI APPTEC CO., LTD (CN) 2018-11-15 — — US disclosed
EP-2682409-B1 DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-07-05 — — EP disclosed
US-9243077-B2 Derivative of hyaluronic acid modified with amino-carboxylic acid CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-26 — — US disclosed
WO-2012118189-A1 HYALURONIC ACID DERIVATIVE MODIFIED BY AMINO-CARBONIC ACID 中外製薬株式会社 (JP) 2012-09-07 — — WO disclosed
EP-0484437-A4 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION SEARLE & CO (US) 1994-06-01 — — EP disclosed
EP-0484437-A1 RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION G.D. Searle & Co. (US) 1992-05-13 — — EP disclosed
US-4299820-A CARDIOVASCULAR DISORDERS PFIZER INC. (US) 1981-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327367-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC FOLH1 1780/4885NAALAD2 413/4885SRC 1844/4885
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC FOLH1 1780/4885NAALAD2 413/4885SRC 1844/4885
US-20030220521-A1 Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension GLS, APEH, GGH FOLH1 9/4885NAALAD2 38/4885SRC 3036/4885
US-20230133667-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC FOLH1 1780/4885NAALAD2 413/4885SRC 1844/4885
US-20040101523-A1 Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension GLS, DBH, APEH FOLH1 9/4885NAALAD2 80/4885SRC 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.